Altimmune slumps after mid-stage data for liver disease drug

Altimmune

26/06/2025 13:22

** Shares of drug developer Altimmune ALT.O fall 62% to $2.94 premarket

** Co says its experimental obesity drug, pemvidutide helped  patients with a type of fatty liver disease achieve disease resolution without worsening of liver scarring in a mid-stage study

** However, the drug does not show statistically significant improvement in liver scarring or fibrosis in patients with the condition, metabolic dysfunction-associated steatohepatitis (MASH)  - ALT

** While the overall data looks good, "missing on statistical significance for fibrosis will be hard for investors to look past" says Citzensbank analyst Jonathan Wolleben

** Up to last close, stock up ~7% YTD

 (Reporting by Mariam Sunny in Bengaluru)

 ((Mariam.ESunny@thomsonreuters.com;))